TY - JOUR
T1 - 胆道肿瘤临床实践指南(英文第三版)
AU - Nagino, Masato
AU - Hirano, Satoshi
AU - Yoshitomi, Hideyuki
AU - Aoki, Taku
AU - Uesaka, Katsuhiko
AU - Unno, Michiaki
AU - Ebata, Tomoki
AU - Konishi, Masaru
AU - Sano, Keiji
AU - Shimada, Kazuaki
AU - Shimizu, Hiroaki
AU - Higuchi, Ryota
AU - Wakai, Toshifumi
AU - Isayama, Hiroyuki
AU - Okusaka, Takuji
AU - Tsuyuguchi, Toshio
AU - Hirooka, Yoshiki
AU - Furuse, Junji
AU - Maguchi, Hiroyuki
AU - Suzuki, Kojiro
AU - Yamazaki, Hideya
AU - Kijima, Hiroshi
AU - Yanagisawa, Akio
AU - Yoshida, Masahiro
AU - Yokoyama, Yukihiro
AU - Mizuno, Takashi
AU - Endo, Itaru
N1 - Publisher Copyright:
Copyright © 2021 by the Chinese Medical Association.
PY - 2021/4/20
Y1 - 2021/4/20
N2 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version in 2014. In this 3rd version, clinical questions (CQs) were proposed on six topics. The recommendation, grade for recommendation, and statement for each CQ were discussed and finalized by an evidence-based approach. Recommendations were graded as grade 1 (strong) or grade 2 (weak) according to the concepts of the grading of recommendations assessment, development, and evaluation system. The 31 CQs covered the six topics: (1) prophylactic treatment, (2) diagnosis, (3) biliary drainage, (4) surgical treatment, (5) chemotherapy, and (6) radiation therapy. In the 31 CQs, 14 recommendations were rated strong and 14 recommendations weak. The remaining three CQs had no recommendation. Each CQ includes a statement of how the recommendations were graded. This latest guideline provides recommendations for important clinical aspects based on evidence. Future collaboration with the cancer registry will be key for assessing the guidelines and establishing new evidence.
AB - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version in 2014. In this 3rd version, clinical questions (CQs) were proposed on six topics. The recommendation, grade for recommendation, and statement for each CQ were discussed and finalized by an evidence-based approach. Recommendations were graded as grade 1 (strong) or grade 2 (weak) according to the concepts of the grading of recommendations assessment, development, and evaluation system. The 31 CQs covered the six topics: (1) prophylactic treatment, (2) diagnosis, (3) biliary drainage, (4) surgical treatment, (5) chemotherapy, and (6) radiation therapy. In the 31 CQs, 14 recommendations were rated strong and 14 recommendations weak. The remaining three CQs had no recommendation. Each CQ includes a statement of how the recommendations were graded. This latest guideline provides recommendations for important clinical aspects based on evidence. Future collaboration with the cancer registry will be key for assessing the guidelines and establishing new evidence.
KW - Biliary tract cancer
KW - Clinical practice
KW - Guideline
UR - http://www.scopus.com/inward/record.url?scp=85105810225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105810225&partnerID=8YFLogxK
U2 - 10.3760/cma.j.cn115610-20210303-00107
DO - 10.3760/cma.j.cn115610-20210303-00107
M3 - 学術論文
AN - SCOPUS:85105810225
SN - 1673-9752
VL - 20
SP - 359
EP - 375
JO - Chinese Journal of Digestive Surgery
JF - Chinese Journal of Digestive Surgery
IS - 4
ER -